RT Journal Article
SR Electronic
T1 Clinical accuracy of SARS-CoV-2 rapid antigen testing in screening children and adolescents in comparison to RT-qPCR, November 2020 to September 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.07.22281809
DO 10.1101/2022.11.07.22281809
A1 Krone, Manuel
A1 Wagenhäuser, Isabell
A1 Knies, Kerstin
A1 Hofmann, Daniela
A1 Engels, Geraldine
A1 Taurines, Regina
A1 McDonogh, Miriam
A1 Flemming, Sven
A1 Meyer, Thomas
A1 Böhm, Hartmut
A1 Scherzad, Agmal
A1 Eisenmann, Michael
A1 Rauschenberger, Vera
A1 Gabel, Alexander
A1 Petri, Nils
A1 Reusch, Julia
A1 Forster, Johannes
A1 Weißbrich, Benedikt
A1 Dölken, Lars
A1 Kurzai, Oliver
A1 Vogel, Ulrich
A1 Härtel, Christoph
A1 Liese, Johannes
A1 Andres, Oliver
YR 2022
UL http://medrxiv.org/content/early/2022/11/10/2022.11.07.22281809.abstract
AB Background Rapid antigen detection tests (RDT) are an easily accessible, feasible, inexpensive, and point-of-care method in SARS-CoV-2 diagnostics – established in adults as well as in children and adolescents. Despite this, large-scale data of clinical performance in the paediatric population especially regarding the influence of SARS-CoV-2 virus variants of concern (VOC) and COVID-19 vaccination on test accuracy is rare.Methods This single-centre prospective diagnostic study evaluates three RDT (NADAL®, Panbio™, MEDsan®) in comparison to quantitative reverse transcription polymerase chain reaction (RT-qPCR). 9,760 oropharyngeal screening samples regarding SARS-CoV-2 VOC and COVID-19 vaccination in paediatric hospitalised patients aged younger than 18 years were enrolled.Findings RDT sensitivity was 44·7% (157/351, 95% CI 39·6%–50·0%) compared to the reference standard RT-qPCR, specificity 99·8% (9,392/9,409, 95% CI 99·7%–99·9%). Most SARS-CoV-2 infections considered were caused by Omicron VOC. Diagnostic accuracy of RDT depended on specimen containing viral load with a decreasing RDT sensitivity by descending viral load, corresponding with a significantly impaired sensitivity in asymptomatic children. A sensitivity of 71·0% was obtained for a viral load higher than 106 SARS-CoV-2 RNA copies per ml suggested as infectivity threshold. No significant differences in RDT sensitivity could be observed regarding gender, symptoms, COVID-19 vaccination status, and VOC.Interpretation In a paediatric population, RDT have proven to reliably detect potentially highly infectious patients with a viral load of at least 106 SARS-CoV-2 RNA copies per ml. Due to the low sensitivity in asymptomatic individuals, the usefulness of RDT seems limited in large-scale SARS-CoV-2 screening programs.Funding Federal Ministry for Education and Science (BMBF), Free State of BavariaCompeting Interest StatementManuel Krone receives honoraria from Abbott outside the submitted work. None of the other authors has any conflicts of interests to declare.Funding StatementThis study was funded by the Federal Ministry for Education and Science (BMBF) via a grant provided to the University Hospital of Wuerzburg by the Network University Medicine on COVID-19 (B-FAST, grant-No 01KX2021), by the Bavarian Staten Ministry of Health and Care via Bay-VOC as well as by the Free State of Bavaria with COVID-research funds provided to the University of Wuerzburg, Germany. Nils Petri is supported by the German Research Foundation (DFG) funded scholarship UNION CVD. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics committee of the University of Wuerzburg considered the study protocol and waived the need to formally apply for ethical clearance due to the study design (File 20220602 01).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual participant data that underlie the results reported in this article after deidentification is available on request immediately following publication ending 5 years following article publication to researchers who provide a methodological sound proposal to achieve aims in the approved proposal. Proposals should be directed to krone_m@ukw.de.